Physician profile
Richard Eusebio
NPI 1427465608
$6,494.31
in general payments reported to CMS, 2019-2025
18 companies · $867 in 2025
The $867 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $230 · 2021: $1,959 · 2022: $1,471 · 2023: $851 · 2024: $693 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,066.05 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Bausch & Lomb Americas INC. | $1,458.45 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $549.45 | 2019-2021 | |
| Allergan, INC. | $381.92 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $264.71 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $255.12 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $241.33 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $212.00 | 2021-2023 | Lipiflow System Activator (Disposable) |
| Sun Pharmaceutical Industries INC. | $177.98 | 2020-2025 | |
| Glaukos Corporation | $162.64 | 2025 | Photrexa Viscous and Photrexa |
| Ivantis, INC | $145.57 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $139.94 | 2022 | |
| Horizon Therapeutics Plc | $121.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $107.96 | 2019-2023 | |
| Rxsight INC | $103.91 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $76.28 | 2019-2020 | |
| Shire North American Group INC | $15.86 | 2019 | |
| Coopervision INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Eusebio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.